Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed...

{ "method": "GET", "queryParams": { "condition": "Disease — e.g. \"Alzheimer Disease\" | \"Sepsis\" | \"ALS\" | \"Depression\" | \"NASH\"", "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)" }, "type": "http" }

{ "errors": { "400": { "description": "Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints.", "example": { "error": "invalid request" } }, "402": { "description": "Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free." }, "500": { "description": "Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit.", "example": { "error": "upstream_failed" } } }, "example": { "failure_taxonomy": { "operational_failures": { "examples": [ "COVID-19 disruption, enrollment failures in rare AD subpopulations" ], "pct": 4 }, "safety_termination": { "examples": [ "ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting" ], "key_trials": [ "Aducanumab Phase 3 dose arm" ], "pct": 8 }, "wrong_endpoint": { "examples": [ "ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard" ], "key_trials": [ "Multiple agents 2010-2020" ], "pct": 18 }, "wrong_patient_population": { "examples": [ "Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms" ], "key_trials": [ "Bapineuzumab (mild-moderate vs. early)" ], "pct": 28 }, "wrong_target_or_hypothesis": { "examples": [ "Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade" ], "key_trials": [ "Solanezumab", "Verubecestat", "Atabecestat" ], "pct": 42 } }, "historical_success_rates": { "overall_clinical_success_pct": 3.4, "phase2_to_phase3_pct": 31, "phase3_to_approval_pct": 11, "vs_all_diseases_benchmark": "Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)" }, "lessons_learned": [ "Early intervention is critical — treat pre-symptomatic or MCI only", "Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)", "CDR-SB global score now accepted primary endpoint by FDA (post-2018)", "ARIA management protocols must be pre-specified — not post-hoc", "Combination approaches (amyloid + tau + neuroinflammation) likely needed" ], "query_summary": { "condition": "Alzheimer Disease", "trials_analyzed": 78 }, "successful_design_principles": "CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration.", "what_still_might_fail": [ "Tau-targeting agents if amyloid clearance alone sufficient", "Agents tested in wrong disease stage despite lessons", "CNS inflammation approaches without biomarker stratification" ] }, "type": "json" }